ERBB2 and breast carcinoma: It received approval as an adjuvant therapy when used in combination with anthracycline- or a taxane-based chemotherapy for HER2-positive breast cancer treatment, and in metastatic HER2-positive breast cancer as a monotherapy or in combination with paclitaxel [36].